Demographic and last-visit treatment characteristics of patients with SLE, RA and APS with and without 2nd rheumatic and/or non-rheumatic illness AI in cohort 1<colcnt=9>
| Diagnosis (N) | Overlap | No. | Mean age years | Female % | White % | Steroid % | HCQ % | Immun % |
|---|---|---|---|---|---|---|---|---|
| SLE (399) | No overlap | 265 | 42.1 | 94 | 66 | 59 | 55 | 29 |
| Overlap | 134 | 47.1**** | 90 | 71 | 47* | 42* | 25 | |
| RA (198) | No overlap | 147 | 54.7 | 86 | 74 | 47 | 16 | 61 |
| Overlap | 51 | 54.3 | 100*** | 76 | 51 | 37*** | 57 | |
| Sjögren's (130) | No overlap | 59 | 51.6 | 95 | 88 | 29 | 30 | 11 |
| Overlap | 71 | 48.4 | 95 | 75* | 28 | 30 | 20 | |
| APS (208) | No overlap | 145 | 46.9 | 70 | 94 | 23 | 23 | 8 |
| Overlap | 63 | 46.4 | 75 | 86 | 41** | 37* | 19* |
Patients with two or more diagnoses are counted in each relevant diagnosis group. Statistically significant differences are shown in bold.
Differs from those with no overlap, *p<0.05, **p<0.01, ***p<0.005, ****p<0.0005.
AI, autoimmune illness; APS, antiphospholipid syndrome; HCQ, hydroxychloroquine; Immun, immunosuppressive agent; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.